title: Chromatin nucleoprotein complexes containing tightly bound c-abl, p53 and bcl-2 gene sequences: correlation with progression of chronic myelogenous leukemia.
abstract: We previously developed a technique to isolate subchromatin nucleoprotein complexes (NPC) that contain tightly bound genes and enzymatic activities. NPC fractions (NPCF) were prepared by directly treating isolated nuclei with MspI to generate six NPCF (S1, M1, S2, M2, 0.1K and R). The NPCF have been used to predict the potential efficacy of interferon-alpha (IFN-alpha) treatment in patients with chronic myelogenous leukemia (CML) [Nicolson et al., Gene 159 (1995) 105-111]. Here the NPCF were probed for the presence of tightly bound c-abl, p53 and bcl-2 genes. We found that the NPCF isolated from the nuclei of leukocytes of normal individuals rarely contained detectable quantities of tightly-bound c-abl, p53 or blc-2 genes or gene sequences, whereas in CML nuclei these genes were often found in tight association with multiple NPCF. Examination of NPCF isolated from the leukocyte nuclei from patients with highly progressive CML for the presence of the three genes revealed that more NPCF contained the three tightly-bound genes than leukocyte NPCF from patients with stable or less progressed CML. These data suggest that as CML progresses to more malignant states, oncogenes, suppressor genes and apoptosis-associated genes become tightly associated with NPCF.
authors.affiliation: Department of Tumor Biology, University of Texas M.D. Anderson Cancer Center, Houston 77030, USA.
authors.forename: N L
authors.initials: NL
authors.lastname: Nicolson
authors.forename: M
authors.initials: M
authors.lastname: Talpaz
authors.forename: G L
authors.initials: GL
authors.lastname: Nicolson
mesh_terms: D000328:Adult; D002467:Cell Nucleus / Q000737:chemistry / Q000235:genetics; D002843:Chromatin / Q000737:chemistry / Q000235:genetics; D018076:DNA, Complementary; D018450:Disease Progression; D016313:Genes, abl; D016158:Genes, p53; D006801:Humans; D016898:Interferon-alpha / Q000627:therapeutic use; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy / Q000235:genetics*; D007962:Leukocytes / Q000737:chemistry / Q000502:physiology*; D009693:Nucleic Acid Hybridization; D009698:Nucleoproteins / Q000378:metabolism; D011518:Proto-Oncogene Proteins / Q000235:genetics*; D019253:Proto-Oncogene Proteins c-bcl-2; D016896:Treatment Outcome
chemical_list: D002843:Chromatin; D018076:DNA, Complementary; D016898:Interferon-alpha; D009698:Nucleoproteins; D011518:Proto-Oncogene Proteins; D019253:Proto-Oncogene Proteins c-bcl-2